IDENTIFICATION OF ETHR INHIBITOR TARGETING MYCOBACTERIUM TUBERCULOSIS: AN INSIGHT FROM MOLECULAR DOCKING STUDY

PAVAN KUMAR POLEBOYINA; SMITA C PAWAR

doi:10.22159/ajpcr.2022.v15i3.43397

Authors

PAVAN KUMAR POLEBOYINA Department of Genetics and Biotechnology, University College of Science, Osmania University, Hyderabad, Telangana, India.
SMITA C PAWAR Department of Genetics and Biotechnology, University College of Science, Osmania University, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i3.43397

Keywords:

Mycobacterium Tuberculosis, EthR, Ethambutol, Isoniazid, Clofazimine, Ethionamide, Molecular Docking

Abstract

Objective: Mycobacterium tuberculosis (MTB) is a pathogenic bacterium of the Mycobacteriaceae family that causes TB. EthR is a transcriptional regulator which is involved in the repression of the monooxygenase EthA which is responsible for the formation of the active metabolite of Eth. Inhibitors of the EthR DNA binding protein induce a conformational change in this repressor, thus preventing its binding to DNA operator, consequently resulting in increased transcription of EthA and bioactivation of Eth.

Methods: In this study, we used first-line and second-line drugs and their analogues to validate the binding affinity of EthR DNA binding protein of MTB. Molegro Virtual Docker (MVD) is utilized for virtual screening and validation of MolDoc, Rerank, and hydrogen bond parameters of ETH, isoniazid (INH), clofazimine (CLF), and its modified derivatives to the EthR DNA binding protein of MTB. The modified molecules; ETH4, INZ2, CLF3, and CLF4 show more binding affinities than that of native compounds ETH, INH, and CLF to the EthR DNA binding protein of MTB. The top scoring compound was docked by auto dock vina in PyRx to get the best conformer pose for intermolecular interactions.

Results: CLF4 had the best lowest MolDock score -176.29kcal/mol and H-bonding energy -6.89kcal/mol in the MVD virtual screening. The best conformer pose generated by PyRx was shown -7.1 binding affinity and ligand generated hydrogen bond interactions with THR130 and LYS68, respectively, which stabilized the ligand in the active site of EthR protein.

Conclusion: We concluded that CLF4 has shown better inhibitory efficacy than other compounds towards EthR protein. However, these results need to be further substantiated through in vitro and in vivo experimental studies.

Downloads

Download data is not yet available.

References

Wong YJ, Noordin NM, Keshavjee S, Lee SW. Impact of latent tuberculosis infection on health and wellbeing: A systematic review and meta-analysis. Eur Respir Rev 2021;30:1-11.

Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003;71:5831-44.

Sakai S, Kauffman KD, Oh S, Nelson CE, Iii CE, Barber DL. MAIT cell-directed therapy of Mycobacterium tuberculosis infection. Mucosal Immunol 2021;14:199-208.

Blumberg HM, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. J Am Med Assoc 2005;293:2776-84.

Grüber G. Introduction: Novel insights into TB research and drug discovery. Prog Biophys Mol Biol 2020;152:2-5.

Sawicki R, Ginalska G. Mycobacterium tuberculosis topoisomerases and EthR as the targets for new anti-TB drugs development. Future Med Chem 2019;11:2193-203.

Chan D, Seetoh WG, McConnell BN, Matak-Vinković D, Thomas SE, Mendes V, et al. Structural insights into the EthR-DNA interaction using native mass spectrometry. Chem Commun (Camb) 2017;53:3527-30.

Villemagne B, MacHelart A, Tran NC, Flipo M, Moune M, Leroux F, et al. Fragment-based optimized EthR inhibitors with in vivo ethionamide boosting activity. ACS Infect Dis 2020;6:366-78.

Tanina A, Wohlkönig A, Soror SH, Flipo M, Villemagne B, Prevet H, et al. A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR. Biochim Biophys Acta Proteins Proteom 2019;1867:248-58.

Willand N, Dirié B, Carette X, Bifani P, Singhal A, Desroses M, et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med 2009;15:537-44.

Ethambutol. Monash University. Available from: https://www. research.monash.edu/en/publications/ethambutol [Last accessed on 2021 Jun 28].

Slayden RA, Barry CE. The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect 2000;2:659-69.

Gopal M, Padayatchi N, Metcalfe JZ, O’Donnell MR. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013;17:1001-7.

Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat Rev Drug Discov 2004;3:935-49.

RCSB PDB: Homepage. Available from: https://www.rcsb.org [Last accessed on 2021 Jun 24].

PubChem. Available from: https://www.pubchem.ncbi.nlm.nih.gov [Last accessed on 2021 Jun 24].

Daoud I, Melkemi N, Salah T, Ghalem S. Combined QSAR, molecular docking and molecular dynamics study on new acetylcholinesterase and butyrylcholinesterase inhibitors. Comput Biol Chem. 2018;74:304-26.

Thomsen R, Christensen MH. MolDock: A new technique for high-accuracy molecular docking. J Med Chem 2006;49:3315-21.

Data M. Modeller, Macs in Chemistry. Available from: https://www. macinchem.org/blog/files/671a3395f65b525e75347a60edf7935e-236. php [Last accessed on 2021 Jun 24].

Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-50.

Sadeghi F, Afkhami A, Madrakian T, Ghavami R. Computational study to select the capable anthracycline derivatives through an overview of drug structure-specificity and cancer cell line-specificity. Chem Pap 2021;75:523-38.

Swiss PDB. Viewer-home. Available from: https://www.spdbv.vital-it. ch [Last accessed on 2021 Jun 24].

Singh SP, Deb CR, Ahmed SU, Saratchandra Y, Konwar BK. Molecular docking simulation analysis of the interaction of dietary flavonols with heat shock protein 90. J Biomed Res 2015;30:67-74.

Kumar P, Shailima P, Ravinder R, Akbar D. Screening and identification of potential iNOS inhibitors to curtail cervical cancer progression: An in silico drug repurposing approach. Appl Biochem Biotechnol 2021;194:570-86.

Pires DE, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066-72.

Swiss ADME. Available from: http://www.swissadme.ch [Last accessed on 2021 Jul 03].

Molinspiration. Cheminformatics. Available from: https://www. molinspiration.com [Last accessed on 2021 Jul 03].

Salmaso V, Moro S. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: An overview. Front Pharmacol 2018;9:923.

Yang JM, Chen CC. GEMDOCK: A generic evolutionary method for molecular docking. Proteins 2004;55:288-304.